Evaluation of the de-regulated signaling pathways involved in the pathogenesis of T-ALL and DLBCL will open new possibilities for targeted therapies.<\/em><\/p><\/div><\/div> T-lineage acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of pediatric and 25% of adult ALL cases. Our research interest focuses on identifying therapeutic targets in this disease. The research topics include: (i) evaluating the role of aberrant Hedgehog (Hh) signaling in T-ALL through gene knock-out studies complimented with gene expression profiling studies and quantitative proteomics; (ii) identifying pathways implicated in patient survival\/prognosis and proteins associated with drug resistance in Diffuse Large B-cell Lymphoma (DLBCL) through a novel proteomics approach based on Forward Phase Protein Arrays (FPPA) applicable to routine FFPE specimens; (iii) identifying novel metabolic vulnerabilities in T-ALL.<\/p> Approximately 20% of pediatric and 50% of adult T-ALL cases still relapse and ultimately die because of refractory disease, underscoring the need to identify molecular mechanisms responsible for disease progression and to develop more effective anti-leukemic drugs. The better understanding of the mechanistic role of each of these pathways lay the grounds for targeted combination therapies incorporating specific inhibitors to conventional anti-leukemic drugs. Amongst DLBCL patients, even with GC-B type, >30% relapse after standard R-CHOP, so the identification of resistance mechanisms reliable molecular prognostic markers or markers predictive of response will be critical for improving patient survival.<\/p><\/div><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\tResearch topic and background<\/h4>
Main research lines<\/h4>
Conclusions and perspectives<\/h4>